Home » Inyx Receives Exclusive Contract From Kos to Produce Azmacort Inhaler
Inyx Receives Exclusive Contract From Kos to Produce Azmacort Inhaler
April 18, 2005
Inyx, Inc., a specialty pharmaceutical company with
a focus on niche drug delivery technologies and products, announced that it
has received from Kos Pharmaceuticals, Inc. a 10-year contractual relationship
to produce Kos' Azmacort Inhalation Aerosol product line. The exclusive Azmacort
relationship is expected to generate about $10 million in annual revenues to
Inyx.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct